Smarter Screening to Predict Antibiotic Success Before Animal Testing

At a Glance

Researchers at Colorado State University have developed a new way to predict how well antibacterial drugs will work in the body before they reach animal testing. The method links lab-based results to real-world effectiveness, helping scientists choose the most promising drug candidates earlier. It is already used across multiple research programs, including NIH-funded projects and industry collaborations. This approach improves decision-making in drug development for serious infections like tuberculosis and other high-risk bacterial diseases.

Background

Bacterial infections such as tuberculosis, melioidosis, and tularemia remain major global health threats, especially with the rise of multidrug-resistant strains. Traditional drug discovery methods rely heavily on minimal inhibitory concentration (MIC) data, which often fails to predict how a drug will perform in living systems. This gap leads to wasted time and resources advancing ineffective compounds. A more reliable way to connect in vitro testing with in vivo outcomes is critical for accelerating the development of effective treatments.

Overview

This technology introduces a structured framework for evaluating the relationship between in vitro activity and in vivo efficacy of antibacterial compounds. Instead of relying solely on MIC values, the method incorporates additional biological and pharmacological factors to better predict how compounds will perform in animal infection models. By doing so, it enables researchers to prioritize drug candidates with a higher likelihood of success earlier in the development pipeline.

The approach has been applied across at least five drug discovery programs and has supported thousands of compound evaluations. It is particularly useful for identifying small molecule inhibitors targeting bacterial cell division—an underexplored but promising therapeutic pathway. These compounds have shown strong antibacterial activity with low toxicity, and the method helps confirm which candidates are worth advancing to costly and time-intensive in vivo studies.